Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Filomena Castiello"'
Autor:
Nicoletta Potenza, Filomena Castiello, Marta Panella, Giovanni Colonna, Gennaro Ciliberto, Aniello Russo, Susan Costantini
Publikováno v:
PLoS ONE, Vol 11, Iss 6, p e0156908 (2016)
Hepatocellular carcinoma (HCC) is a multi-factorial cancer with a very poor prognosis; therefore, there are several investigations aimed at the comprehension of the molecular mechanisms leading to development and progression of HCC and at the definit
Externí odkaz:
https://doaj.org/article/3fdfe84217fc44738453c06ac0c543e7
Autor:
Paola Stiuso, Nicoletta Potenza, Angela Lombardi, Ida Ferrandino, Antonio Monaco, Silvia Zappavigna, Daniela Vanacore, Nicola Mosca, Filomena Castiello, Stefania Porto, Raffaele Addeo, Salvatore Del Prete, Ferdinando De Vita, Aniello Russo, Michele Caraglia
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 4, Iss C (2015)
Hepatocellular carcinoma (HCC) is the third cause of cancer-related deaths worldwide. Sorafenib is the only approved drug for patients with advanced HCC but has shown limited activity. microRNAs (miRs) have been involved in several neoplasms includin
Externí odkaz:
https://doaj.org/article/8e41873523264ad8b63c164b53361482
Autor:
Antonio Giordano, Filomena Castiello, Carmela Ferri, Paola Stiuso, Daniela Vanacore, Marta Panella, Nicoletta Potenza, Nicola Mosca, Michele Caraglia, Silvia Zappavigna, Aniello Russo
Publikováno v:
Journal of Cellular Physiology. 232:1907-1913
Sorafenib is an antitumor drug for treatment of advanced hepatocellular carcinoma (HCC). It acts as a multikinase inhibitor suppressing cell proliferation and angiogenesis. Human microRNA-125a-5p (miR-125a) is endowed with similar activities and is f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e0650b0e426c1f9fe9882c1d223541c
https://doi.org/10.1002/jcp.25744
https://doi.org/10.1002/jcp.25744
Autor:
Evangelista Sagnelli, Nicola Mosca, Filomena Castiello, Caterina Sagnelli, Aniello Russo, Nicoletta Potenza, Maria Consiglia Trotta, Nicola Coppola, Mariantonietta Pisaturo
Publikováno v:
Biochemical and Biophysical Research Communications. 449:141-145
The hepatitis B virus (HBV) is a widespread human pathogen and chronic HBV infection is a major risk factor for hepatocellular carcinoma (HCC). Some cellular microRNAs are emerging as important regulators of virus-host interaction, indirectly or dire
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28d166d665b11a0cba46b5e12e36ab95
https://doi.org/10.1016/j.bbrc.2014.05.009
https://doi.org/10.1016/j.bbrc.2014.05.009
Autor:
Filomena Castiello, Gennaro Ciliberto, Marta Panella, Susan Costantini, Giovanni Colonna, Aniello Russo, Nicoletta Potenza
Publikováno v:
PLoS ONE, Vol 11, Iss 6, p e0156908 (2016)
PLoS ONE
PLoS ONE
Hepatocellular carcinoma (HCC) is a multi-factorial cancer with a very poor prognosis; therefore, there are several investigations aimed at the comprehension of the molecular mechanisms leading to development and progression of HCC and at the definit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::932cef0e338a9537eee222169e8ab900
http://europepmc.org/articles/PMC4898719?pdf=render
http://europepmc.org/articles/PMC4898719?pdf=render
Autor:
Aniello Russo, Antonio Monaco, Michele Caraglia, Raffaele Addeo, Ida Ferrandino, Silvia Zappavigna, Nicoletta Potenza, Paola Stiuso, Salvatore Del Prete, Angela Lombardi, Ferdinando De Vita, Stefania Porto, Daniela Vanacore, Filomena Castiello, Nicola Mosca
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 4, Iss C (2015)
Hepatocellular carcinoma (HCC) is the third cause of cancer-related deaths worldwide. Sorafenib is the only approved drug for patients with advanced HCC but has shown limited activity. microRNAs (miRs) have been involved in several neoplasms includin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::333889164853dd27fd2c74ee8c07ea8b
http://hdl.handle.net/11588/635719
http://hdl.handle.net/11588/635719
